{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:28:31Z","timestamp":1782458911233,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00228-024-03727-0","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T06:02:21Z","timestamp":1721887341000},"page":"1685-1695","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Neuronal toxicity of monoclonal antibodies (mAbs): an analysis of post-marketing reports from FDA Adverse Event Reporting System (FAERS) safety database"],"prefix":"10.1007","volume":"80","author":[{"given":"Nitin","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekanandan","family":"Kalaiselvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep Kumar","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"issue":"3","key":"3727_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/antib9030034","volume":"9","author":"DJ Zahavi","year":"2020","unstructured":"Zahavi DJ, Weiner LM (2020) Monoclonal antibodies in cancer therapy Antibodies 9(3):34. https:\/\/doi.org\/10.3390\/antib9030034","journal-title":"Monoclonal antibodies in cancer therapy Antibodies"},{"key":"3727_CR2","doi-asserted-by":"publisher","unstructured":"Quinteros DA, Berm\u00fadez JMA, Ravetti S, Cid AG, Allemandi DA, Palma SD (2017) Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery. In: Elsevier eBooks. 807\u2013833. https:\/\/doi.org\/10.1016\/b978-0-323-46143-6.00025-7","DOI":"10.1016\/b978-0-323-46143-6.00025-7"},{"key":"3727_CR3","unstructured":"Antibody therapeutics approved or in regulatory review in the EU or US - the antibody society. 2027 The Antibody Society. https:\/\/www.antibodysociety.org\/resources\/approved-antibodies\/. Accessed 29 Oct 2023"},{"key":"3727_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2019.105566","volume":"188","author":"E Horta","year":"2020","unstructured":"Horta E, Bongiorno C, Ezzeddine M, Neil E (2020) Neurotoxicity of antibodies in cancer therapy: a review. Clin Neurol Neurosurg 188:105566. https:\/\/doi.org\/10.1016\/j.clineuro.2019.105566","journal-title":"Clin Neurol Neurosurg"},{"key":"3727_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107498","volume":"95","author":"C Chen","year":"2021","unstructured":"Chen C, Wu B, Zhang C, Xu T (2021) Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int J Immunopharmacol 95:107498. https:\/\/doi.org\/10.1016\/j.intimp.2021.107498","journal-title":"Int J Immunopharmacol"},{"issue":"4","key":"3727_CR6","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/cancers12040826","volume":"12","author":"S Cirmi","year":"2020","unstructured":"Cirmi S, El A, Letinier L, Navarra M, Salvo F (2020) Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA Adverse Event Reporting System Database (FAERS). Cancers 12(4):826. https:\/\/doi.org\/10.3390\/cancers12040826","journal-title":"Cancers"},{"issue":"3","key":"3727_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/healthcare10030420","volume":"10","author":"MA Khaleel","year":"2022","unstructured":"Khaleel MA, Khan AH, Ghadzi SMS, Adnan AS, Abdallah Q (2022) A standardized dataset of a spontaneous adverse event reporting system. Healthcare 10(3):420. https:\/\/doi.org\/10.3390\/healthcare10030420","journal-title":"Healthcare"},{"key":"3727_CR8","unstructured":"Research CFDEA (2021)\u00a0FDA Adverse Event Reporting System (FAERS) Public Dashboard. U.S. Food And Drug Administration.\u00a0https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard. Accessed 7 Sept 2023"},{"key":"3727_CR9","unstructured":"BioSpace (2022) Global top 10 cancer antibodies by sales 2021. BioSpace.\u00a0https:\/\/www.biospace.com\/article\/global-top-10-cancer-antibodies-by-sales-2021\/. Accessed on 5 Sept 2023"},{"issue":"2","key":"3727_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40199-023-00464-0","volume":"31","author":"A Khurana","year":"2023","unstructured":"Khurana A, Arora MK, Dubey H (2023) Cardiac safety profile of type II kinase inhibitors: analysis of post-marketing reports from databases of European Medicine Agency & World Health Organization. Daru 31(2):107\u2013118. https:\/\/doi.org\/10.1007\/s40199-023-00464-0","journal-title":"Daru"},{"issue":"3","key":"3727_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10618-006-0052-8","volume":"14","author":"GN Noren","year":"2007","unstructured":"Noren GN, Orre R, Bate A, Edwards IR (2007) Duplicate detection in adverse drug reaction surveillance. Data Min Knowl Discov 14(3):305\u2013328. https:\/\/doi.org\/10.1007\/s10618-006-0052-8","journal-title":"Data Min Knowl Discov"},{"issue":"6","key":"3727_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"S Evans","year":"2001","unstructured":"Evans S, Waller PJ, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"3727_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.6339\/jds.201504_13(2).0005","volume":"13","author":"G Singh","year":"2021","unstructured":"Singh G, Tripathi A, Singh S, Singh U, Singh OP (2021) Analysis of child mortality for Muslim women of Uttar Pradesh, India: an application of Bayesian frailty model. J Data Sci 13(2):311\u2013322. https:\/\/doi.org\/10.6339\/jds.201504_13(2).0005","journal-title":"J Data Sci"},{"issue":"6","key":"3727_CR14","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1177\/2168479015589822","volume":"49","author":"V Kalaiselvan","year":"2015","unstructured":"Kalaiselvan V, Tripathi A, Saurabh A et al (2015) Quantitative methods for the identification of signals for individual case safety reports in India. Ther Innov Regul Sci 49(6):898\u2013902. https:\/\/doi.org\/10.1177\/2168479015589822","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"3727_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Noren","year":"2011","unstructured":"Noren GN, Hopstadius J, Bate A (2011) Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res 22(1):57\u201369. https:\/\/doi.org\/10.1177\/0962280211403604","journal-title":"Stat Methods Med Res"},{"issue":"16","key":"3727_CR16","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1212\/wnl.0000000000003238","volume":"87","author":"A Kim","year":"2016","unstructured":"Kim A, Moffatt E, Ursell PC, Devinsky O, Olgin JE, Tseng ZH (2016) Sudden neurologic death masquerading as out-of-hospital sudden cardiac death. Neurology 87(16):1669\u20131673. https:\/\/doi.org\/10.1212\/wnl.0000000000003238","journal-title":"Neurology"},{"key":"3727_CR17","doi-asserted-by":"publisher","unstructured":"Prakash A, Krishnan K (2014) Neurological disorders in the elderly. In: Oxford University Press eBooks. 87\u201392. https:\/\/doi.org\/10.1093\/med\/9780199604999.003.0012","DOI":"10.1093\/med\/9780199604999.003.0012"},{"key":"3727_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1116-x","author":"C Kuate-Tegueu","year":"2015","unstructured":"Kuate-Tegueu C, Clet TB, Jacques D, Yepnjio FN, Fran\u00e7ois DJ, Maturin TT (2015) The pattern of neurological diseases in elderly people in outpatient consultations in Sub-Saharan Africa. BMC Res Notes. https:\/\/doi.org\/10.1186\/s13104-015-1116-x","journal-title":"BMC Res Notes"},{"key":"3727_CR19","unstructured":"European Medicines Agency (2009) Guideline on the use of statistical signal detection methods in the EudraVigilance Data Analysis System.\u00a0http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2009\/11\/WC500011437. Accessed 9 Sept 2023"},{"key":"3727_CR20","unstructured":"Research CFDEA (2018) Good pharmacovigilance practices and pharmacoepidemiologic assessment. U.S. Food And Drug Administration. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment"},{"issue":"3","key":"3727_CR21","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1002\/cam4.5062","volume":"12","author":"Y Shu","year":"2022","unstructured":"Shu Y, Ding Y, He X, Liu Y, Wu P, Zhang Q (2022) Hematological toxicities in PARP inhibitors: a real-world study using FDA Adverse Event Reporting System (FAERS) database. Cancer Med 12(3):3365\u20133375. https:\/\/doi.org\/10.1002\/cam4.5062","journal-title":"Cancer Med"},{"key":"3727_CR22","unstructured":"Research CFDEA (2023)\u00a0FDA Adverse Event Reporting System (FAERS) electronic submissions. U.S. Food And Drug Administration.\u00a0https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-electronic-submissions. Accessed 21 Sept 2023"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03727-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03727-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03727-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T14:03:43Z","timestamp":1728309823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03727-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["3727"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03727-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4245237\/v1","asserted-by":"object"}]},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]},"assertion":[{"value":"10 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}